Dose prescription in carbon ion radiotherapy: How to compare two different RBE-weighted dose calculation systemsSilvia Molinelli, Piero Fossati, Barbara Vischioni et al.|Radiotherapy and Oncology|2016Cited by 91
T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational studyFrancesco Schettini, Lucia Del Mastro, Benedetta Conte et al.|ESMO Open|2021Cited by 22
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective studyGrazia Arpino, Sabino De Placido, Andrea Michelotti et al.|Journal of Cancer Research and Clinical Oncology|2015Cited by 15
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|ESMO Open|2021Cited by 12
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi, Lucia Del Mastro, Lorenzo Gerratana et al.|npj Breast Cancer|2021Cited by 9